1 / 23

Incontro Nazionale Neurofisiologia: Nuove Strategie  

Incontro Nazionale Neurofisiologia: Nuove Strategie   “ Controversie sulla diagnosi e terapia del dolore neuropatico ” Opinioni a confronto. NO. Acido lipoico e dolore neuropatico diabetico. Domenico A. Restivo U.O. di Neurologia P.O. “Nuovo Garibaldi”, Catania.

kineta
Download Presentation

Incontro Nazionale Neurofisiologia: Nuove Strategie  

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Incontro Nazionale Neurofisiologia: Nuove Strategie   “Controversie sulla diagnosi e terapia del dolore neuropatico” Opinioni a confronto NO Acido lipoico e dolore neuropatico diabetico Domenico A. Restivo U.O. di Neurologia P.O. “Nuovo Garibaldi”, Catania

  2. AANEM GUIDELINES - 2011 There is insufficient evidence to support or refute the usefulness of vitamins and alpha-lipoic acid in the treatment of PDN (Level U). BRIL ET AL., 2011

  3. ALA AND NEUROPATHIC PAIN Golbidi et al., 2011

  4. ALA RCTs • ALADIN I • ALADIN III • SYDNEY • NATHAN II • SYDNEY 2 • NATHAN I Misure di outcome inappropriate per valutare il dolore neuropatico

  5. OUTCOME MEASURES IN ALA RCTs • TSS (Total symptoms Score: points: 0-14.64): Sensory symptoms • (Ziegler et al., 2004) • Neuropathy TSS: Sensory symptoms (Bastyr et al., 2002) • TNS (Total Neuropathy Score): Sensory, motor, and autonomic symptoms; Sensory and motor signs; reflexes; QST (vibration); sensory and motor NCS. (Cornblath et al., 1999) • NSS (Neuropathy Symptoms Score): Sensory, motor, and autonomic Symptoms (Dyck et al., 1988) • NIS (Neuropathy Impairment Score): NIS LL:Sensory and motor signs; • Reflexes in the lower limbs; NIS LL + 4: Sensory and motor signs; Reflexes • in the lower limbs+ motor NCS; NIS LL + 5: Sensory and motor signs; Reflexes • in the lower limbs+ motor NCS + QST (vibration); NIS LL + 7: Sensory and motor • signs; Reflexes in the lower limbs+ sensory and motor NCS + QST (vibration) + • AFT (Dyck et al., 1997)

  6. TSS • Patients: 328 • Outcome primario: TSS • Outcome secondario: NSS, • Neuropathy Disability Score • Results: improvement in TSS

  7. ALADIN TSS Significant changes in TSS score

  8. Patienti: 509 Outcome primario: TSS Outcome secondario:NIS, NIS-LL Risuatati: No miglioramento in TSS; SI NIS

  9. NO IMPROVEMENT IN QST Pazienti: 60 vs 60 controlli Outcome primario: TSS Outcome secondario: NIS, NSC, NCS, QST, AF test Risultati: miglioramento significativo in TTS, NIS, NCS

  10. Patients: 181 • Primary Outcome: TSS • Secondary Outcome :individual symptoms of TSS, NIS, NSC, Patient’s • Global Assessment (PGA) • Results: improvement in TSS, individual symptoms of TSS, NSC, PGA

  11. Primary outcome Secondary outcomes

  12. Results: no significant improvement in the primary endpoints Patients: 460 Primary outcome: NIS-LL 7 Secondary outcome: NIS, NIS-LL, NCS, QST

  13. EFFECTS OF ALA ON DIFFERENT OUTCOME MEASURES 20 DPNP PTS Restivo et al., unpublished data

  14. ALA NPSI 20 DPNP PTS NPSI: SIGNIFICANT IMPROVEMENT ONLY FOR DEEP SPONTANEOUS PAIN (PRESSING) AND PARESTHESIA/DYSESTHESIA QUESTO DATO POTREBBE IN QUALCHE MODO SPIEGARE L’ASSENZA DI MIGLIORAMENTO DEL QST DOPO ALA

  15. Neuropatie Dolorose in corso di Diabete PoliNPT sensitiva dolorosa associata a ridotta tolleranza al Glc NPT da iperglicemia o funzionale NPT acuta dolorosa precipitata dal controllo glicemico PoliNPT prevalentemente sensitiva distale e simmetrica NPT delle fibre di piccolo calibro NPT cachettica o NPT dolorosa acuta Anoressia con neuropatia dolorosa acuta Mononeuropatie singole o multiple Radicolopatia toracica multipla dolorosa Radicolo-plessopatia lombosacrale dolorosa acuta Mononeuropatie da intrappolamento NPT oftalmoplegica

  16. POTREBBE L’EFFETTO DELL’ALA DIPENDERE DAL TIPO DI NEUROPATIA ? BPI ALA 15 SFDN PTS; 22 DSP PTS Risposta migliore nei pz con polineuropatia simmetrica sensitiva distale Scarsa risposta in pz con neuropatia prevalentemente a carico delle piccole fibre

  17. Stimulation of distal sensory axons to study the neural impulse generation in individual nerve fibers by-passing the receptor organ The absolute refractory periods (ARP) of single sensory axons is significantly shorter in diabetic patients (Mackel and Brink 2003) The shorter ARP in diabetic nerves may be consistent with reduced nodal Na+ currents (Quasthoff, 1998), which is a consequence of reduction of Na+-K+ ATPase activity, which play an important role in the pathophysiology of DN (Distal Simmetric Polyneuropathy)

  18. The absolute refractory period is the shortest interpulse interval at which an action potential is generated and propagated in response to a second stimulus ALA INCREASE ARP IN DISTAL SIMMETRIC POLYNEUROPATHY ARP No correlation between ARP increase and BPI changes in patients with diabetic distal sensory neuropathy and pain 12 PTS

  19. COSTI IN ITALIA LA TERAPIA PER UN MESE CON ACIDO LIPOICO COSTA CIRCA 20 EURO… HA UN SENSO SOTTOPORRE IL PAZIENTE AD UNA SPESA, NON SEMPRE DA TUTTI SOSTENIBILE, IN ASSENZA DI SICURI BENEFICI E/O SOLO SULLA BASE DEL PRESUPPOSTO CHE: “TANTO NON FA MALE…” ???

  20. CONCLUSIONI NON VI SONO SUFFICIENTI EVIDENZE CHE L’ACIDO LIPOICO POSSA MIGLIORARE IL DOLORE NEUROPATICO ASSOCIATO A DIABETE MELLITO ULTERIORI STUDI RANDOMIZZATI-CONTROLLATI CHE UTILIZZINO MISURE DI OUTCOME PIU’ “SPECIFICHE” SONO NECESSARI PRIMA DI UN SICURO E DEFINITIVO UTILIZZO DELL’ALA SUL DPNP

More Related